U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C16H11ClN4
Molecular Weight 294.738
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ESTAZOLAM

SMILES

ClC1=CC2=C(C=C1)N3C=NN=C3CN=C2C4=CC=CC=C4

InChI

InChIKey=CDCHDCWJMGXXRH-UHFFFAOYSA-N
InChI=1S/C16H11ClN4/c17-12-6-7-14-13(8-12)16(11-4-2-1-3-5-11)18-9-15-20-19-10-21(14)15/h1-8,10H,9H2

HIDE SMILES / InChI

Molecular Formula C16H11ClN4
Molecular Weight 294.738
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/estazolam.html

Estazolam, a triazolobenzodiazepine derivative, is an oral hypnotic agent with anticonvulsant, hypnotic, and muscle relaxant properties. It has been shown in some cases to be more potent than diazepam or nitrazepam. Benzodiazepines bind nonspecifically to benzodiazepine receptors, which affects affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the effects GABA by increasing GABA affinity for the GABA receptor. Binding of the inhibitory neurotransmitter GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell. Used for the short-term management of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. Marketed under the brand names ProSom, Eurodin.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
3.8 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Estazolam

Approved Use

Estazolam is indicated for the short-term management of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings.

Launch Date

8.7186237E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
54.7 ng/mL
1 mg single, oral
dose: 1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ESTAZOLAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
98.6 ng/mL
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ESTAZOLAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
194 ng/mL
4 mg single, oral
dose: 4 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ESTAZOLAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
180 ng/mL
2 mg 2 times / day steady-state, oral
dose: 2 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ESTAZOLAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1050 ng × h/mL
1 mg single, oral
dose: 1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ESTAZOLAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
2060 ng × h/mL
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ESTAZOLAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
4343 ng × h/mL
4 mg single, oral
dose: 4 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ESTAZOLAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
5517 ng × h/mL
2 mg 2 times / day steady-state, oral
dose: 2 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ESTAZOLAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
14.9 h
1 mg single, oral
dose: 1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ESTAZOLAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
14.3 h
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ESTAZOLAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
19 h
4 mg single, oral
dose: 4 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ESTAZOLAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
17 h
2 mg 2 times / day steady-state, oral
dose: 2 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ESTAZOLAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
6 mg 1 times / day single, oral
Highest studied dose
Dose: 6 mg, 1 times / day
Route: oral
Route: single
Dose: 6 mg, 1 times / day
Sources:
healthy, 21-47
n = 60
Health Status: healthy
Age Group: 21-47
Sex: M+F
Population Size: 60
Sources:
2 mg 1 times / day multiple, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 42.9 (18-85)
n = 685
Health Status: unhealthy
Condition: insomnia
Age Group: 42.9 (18-85)
Sex: M+F
Population Size: 685
Sources:
Disc. AE: Illness, Somnolence...
AEs leading to
discontinuation/dose reduction:
Illness
Somnolence (grade 1-2)
Dizziness (grade 1-2)
Sources:
40 mg 1 times / day single, oral
Overdose
Dose: 40 mg, 1 times / day
Route: oral
Route: single
Dose: 40 mg, 1 times / day
Sources:
unknown, unknown
Health Status: unknown
Age Group: unknown
Sex: unknown
Sources:
Disc. AE: Somnolence, Respiratory depression...
AEs leading to
discontinuation/dose reduction:
Somnolence
Respiratory depression
Confusion
Coordination impaired
Slurred speech
Coma
Sources:
AEs

AEs

AESignificanceDosePopulation
Illness Disc. AE
2 mg 1 times / day multiple, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 42.9 (18-85)
n = 685
Health Status: unhealthy
Condition: insomnia
Age Group: 42.9 (18-85)
Sex: M+F
Population Size: 685
Sources:
Dizziness grade 1-2
Disc. AE
2 mg 1 times / day multiple, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 42.9 (18-85)
n = 685
Health Status: unhealthy
Condition: insomnia
Age Group: 42.9 (18-85)
Sex: M+F
Population Size: 685
Sources:
Somnolence grade 1-2
Disc. AE
2 mg 1 times / day multiple, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 42.9 (18-85)
n = 685
Health Status: unhealthy
Condition: insomnia
Age Group: 42.9 (18-85)
Sex: M+F
Population Size: 685
Sources:
Coma Disc. AE
40 mg 1 times / day single, oral
Overdose
Dose: 40 mg, 1 times / day
Route: oral
Route: single
Dose: 40 mg, 1 times / day
Sources:
unknown, unknown
Health Status: unknown
Age Group: unknown
Sex: unknown
Sources:
Confusion Disc. AE
40 mg 1 times / day single, oral
Overdose
Dose: 40 mg, 1 times / day
Route: oral
Route: single
Dose: 40 mg, 1 times / day
Sources:
unknown, unknown
Health Status: unknown
Age Group: unknown
Sex: unknown
Sources:
Coordination impaired Disc. AE
40 mg 1 times / day single, oral
Overdose
Dose: 40 mg, 1 times / day
Route: oral
Route: single
Dose: 40 mg, 1 times / day
Sources:
unknown, unknown
Health Status: unknown
Age Group: unknown
Sex: unknown
Sources:
Respiratory depression Disc. AE
40 mg 1 times / day single, oral
Overdose
Dose: 40 mg, 1 times / day
Route: oral
Route: single
Dose: 40 mg, 1 times / day
Sources:
unknown, unknown
Health Status: unknown
Age Group: unknown
Sex: unknown
Sources:
Slurred speech Disc. AE
40 mg 1 times / day single, oral
Overdose
Dose: 40 mg, 1 times / day
Route: oral
Route: single
Dose: 40 mg, 1 times / day
Sources:
unknown, unknown
Health Status: unknown
Age Group: unknown
Sex: unknown
Sources:
Somnolence Disc. AE
40 mg 1 times / day single, oral
Overdose
Dose: 40 mg, 1 times / day
Route: oral
Route: single
Dose: 40 mg, 1 times / day
Sources:
unknown, unknown
Health Status: unknown
Age Group: unknown
Sex: unknown
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
yes [Inhibition 10 uM]
yes [Inhibition 10 uM]
yes
Drug as victim
PubMed

PubMed

TitleDatePubMed
Diazepam-induced decrease in histamine turnover in mouse brain.
1986 May 27
Inhibition of the binding and the behavioral effects of thyrotropin-releasing hormone (TRH) by the triazolobenzodiazepines.
1988 May
Central serotonergic mechanisms on head twitch response induced by benzodiazepine receptor agonists.
2001
Sensitive method for the detection of 22 benzodiazepines by gas chromatography-ion trap tandem mass spectrometry.
2002 Apr 19
Antidepressant-related hypomania in a patient with premenstrual dysphoric disorder.
2002 Oct
Determination of hypnotic benzodiazepines (alprazolam, estazolam, and midazolam) and their metabolites in rat hair and plasma by reversed-phase liquid-chromatography with electrospray ionization mass spectrometry.
2003 Jan 15
Treatment of phlegm- and heat-induced insomnia by acupuncture in 120 cases.
2003 Mar
Overview of the therapeutic management of insomnia with zolpidem.
2004
Simultaneous determination of albendazole and its major active metabolite in human plasma using a sensitive and specific liquid chromatographic-tandem mass spectrometric method.
2004 Jun 29
Prediction of genotoxicity of chemical compounds by statistical learning methods.
2005 Jun
Design and synthesis of new 2-substituted-5-(2-benzylthiophenyl)-1,3,4-oxadiazoles as benzodiazepine receptor agonists.
2005 Jun 15
Determination of four benzodiazepine residues in pork using multiwalled carbon nanotube solid-phase extraction and gas chromatography-mass spectrometry.
2006 Dec 8
[Analysis of 37 drugs in whole blood by HPLC after solid phase extraction].
2006 Oct 15
Indiplon in the treatment of sleep disorders.
2007 Dec
Sensitive and selective liquid chromatography-tandem mass spectrometry method for the quantification of aniracetam in human plasma.
2007 Oct 15
Abdominal acupuncture for insomnia in women: a randomized controlled clinical trial.
2008
High performance liquid chromatography-tandem mass spectrometric determination of rupatadine in human plasma and its pharmacokinetics.
2008 Aug 5
Simultaneous determination of naringenin and hesperetin in rats after oral administration of Da-Cheng-Qi decoction by high-performance liquid chromatography-tandem mass spectrometry.
2008 Jul
Auricular acupuncture for insomnia: a systematic review.
2008 Nov
[Effect of modified xiaoyao powder for improving sleep in patients with psychological stress insomnia].
2009 Mar
Drugs associated with more suicidal ideations are also associated with more suicide attempts.
2009 Oct 2
Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders.
2009 Winter
Four cases of dysthymic disorder and general malaise successfully treated with traditional herbal (kampo) medicines: kamiuntanto.
2010
5-(4-Chloro-phen-yl)-3-(2,4-dimethyl-thiazol-5-yl)-1,2,4-triazolo[3,4-a]isoquinoline.
2010 Apr 10
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.
2010 Dec
A validated method for simultaneous screening and quantification of twenty-three benzodiazepines and metabolites plus zopiclone and zaleplone in whole blood by liquid-liquid extraction and ultra-performance liquid chromatography- tandem mass spectrometry.
2010 Jul-Aug
Patents

Sample Use Guides

In Vivo Use Guide
Usual Adult Dose for Insomnia 1 to 2 mg orally at bedtime
Route of Administration: Oral
In Vitro Use Guide
Incubation of rabbit PRP with etizolam for 2 min before administration of aggregating agents inhibited aggregation induced by PAF (190 nM) with an IC50 of 3.8 uM. Etizolam at a higher concentration (300 uM) only slightly in hibited ADP (15 uM) and arachidonic acid-induced aggregation
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:23:27 UTC 2023
Edited
by admin
on Fri Dec 15 15:23:27 UTC 2023
Record UNII
36S3EQV54C
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ESTAZOLAM
INN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
NSC-290818
Code English
ESTAZOLAM [USAN]
Common Name English
ABBOTT-47631
Code English
ESTAZOLAM [VANDF]
Common Name English
ESTAZOLAM [IARC]
Common Name English
ESTAZOLAM [USP MONOGRAPH]
Common Name English
ESTAZOLAM [MI]
Common Name English
Estazolam [WHO-DD]
Common Name English
ESTAZOLAM CIV [USP-RS]
Common Name English
ESTAZOLAM [JAN]
Common Name English
ESTAZOLAM CIV
USP-RS  
Common Name English
8-Chloro-6-phenyl-4H-S-triazolo[4,3-a][1,4]benzodiazepine
Systematic Name English
4H-(1,2,4)TRIAZOLO(4,3-A)(1,4)BENZODIAZEPINE, 8-CHLORO-6-PHENYL-
Systematic Name English
ESTAZOLAM [MART.]
Common Name English
estazolam [INN]
Common Name English
PROSOM
Brand Name English
ESTAZOLAM [ORANGE BOOK]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C1012
Created by admin on Fri Dec 15 15:23:28 UTC 2023 , Edited by admin on Fri Dec 15 15:23:28 UTC 2023
WHO-ATC N05CD04
Created by admin on Fri Dec 15 15:23:28 UTC 2023 , Edited by admin on Fri Dec 15 15:23:28 UTC 2023
NDF-RT N0000007542
Created by admin on Fri Dec 15 15:23:28 UTC 2023 , Edited by admin on Fri Dec 15 15:23:28 UTC 2023
LIVERTOX NBK548660
Created by admin on Fri Dec 15 15:23:28 UTC 2023 , Edited by admin on Fri Dec 15 15:23:28 UTC 2023
WHO-VATC QN05CD04
Created by admin on Fri Dec 15 15:23:28 UTC 2023 , Edited by admin on Fri Dec 15 15:23:28 UTC 2023
NDF-RT N0000175694
Created by admin on Fri Dec 15 15:23:28 UTC 2023 , Edited by admin on Fri Dec 15 15:23:28 UTC 2023
DEA NO. 2756
Created by admin on Fri Dec 15 15:23:28 UTC 2023 , Edited by admin on Fri Dec 15 15:23:28 UTC 2023
Code System Code Type Description
NCI_THESAURUS
C47520
Created by admin on Fri Dec 15 15:23:28 UTC 2023 , Edited by admin on Fri Dec 15 15:23:28 UTC 2023
PRIMARY
MESH
D004949
Created by admin on Fri Dec 15 15:23:28 UTC 2023 , Edited by admin on Fri Dec 15 15:23:28 UTC 2023
PRIMARY
USAN
CC-24
Created by admin on Fri Dec 15 15:23:28 UTC 2023 , Edited by admin on Fri Dec 15 15:23:28 UTC 2023
PRIMARY
PUBCHEM
3261
Created by admin on Fri Dec 15 15:23:28 UTC 2023 , Edited by admin on Fri Dec 15 15:23:28 UTC 2023
PRIMARY
DAILYMED
36S3EQV54C
Created by admin on Fri Dec 15 15:23:28 UTC 2023 , Edited by admin on Fri Dec 15 15:23:28 UTC 2023
PRIMARY
EVMPD
SUB07241MIG
Created by admin on Fri Dec 15 15:23:28 UTC 2023 , Edited by admin on Fri Dec 15 15:23:28 UTC 2023
PRIMARY
DRUG CENTRAL
1056
Created by admin on Fri Dec 15 15:23:28 UTC 2023 , Edited by admin on Fri Dec 15 15:23:28 UTC 2023
PRIMARY
RS_ITEM_NUM
1249905
Created by admin on Fri Dec 15 15:23:28 UTC 2023 , Edited by admin on Fri Dec 15 15:23:28 UTC 2023
PRIMARY
IUPHAR
7550
Created by admin on Fri Dec 15 15:23:28 UTC 2023 , Edited by admin on Fri Dec 15 15:23:28 UTC 2023
PRIMARY
RXCUI
4077
Created by admin on Fri Dec 15 15:23:28 UTC 2023 , Edited by admin on Fri Dec 15 15:23:28 UTC 2023
PRIMARY RxNorm
LACTMED
Estazolam
Created by admin on Fri Dec 15 15:23:28 UTC 2023 , Edited by admin on Fri Dec 15 15:23:28 UTC 2023
PRIMARY
DRUG BANK
DB01215
Created by admin on Fri Dec 15 15:23:28 UTC 2023 , Edited by admin on Fri Dec 15 15:23:28 UTC 2023
PRIMARY
SMS_ID
100000082361
Created by admin on Fri Dec 15 15:23:28 UTC 2023 , Edited by admin on Fri Dec 15 15:23:28 UTC 2023
PRIMARY
WIKIPEDIA
ESTAZOLAM
Created by admin on Fri Dec 15 15:23:28 UTC 2023 , Edited by admin on Fri Dec 15 15:23:28 UTC 2023
PRIMARY
ChEMBL
CHEMBL285674
Created by admin on Fri Dec 15 15:23:28 UTC 2023 , Edited by admin on Fri Dec 15 15:23:28 UTC 2023
PRIMARY
FDA UNII
36S3EQV54C
Created by admin on Fri Dec 15 15:23:28 UTC 2023 , Edited by admin on Fri Dec 15 15:23:28 UTC 2023
PRIMARY
INN
3611
Created by admin on Fri Dec 15 15:23:28 UTC 2023 , Edited by admin on Fri Dec 15 15:23:28 UTC 2023
PRIMARY
ECHA (EC/EINECS)
249-982-4
Created by admin on Fri Dec 15 15:23:28 UTC 2023 , Edited by admin on Fri Dec 15 15:23:28 UTC 2023
PRIMARY
MERCK INDEX
m5027
Created by admin on Fri Dec 15 15:23:28 UTC 2023 , Edited by admin on Fri Dec 15 15:23:28 UTC 2023
PRIMARY Merck Index
EPA CompTox
DTXSID5020572
Created by admin on Fri Dec 15 15:23:28 UTC 2023 , Edited by admin on Fri Dec 15 15:23:28 UTC 2023
PRIMARY
NSC
290818
Created by admin on Fri Dec 15 15:23:28 UTC 2023 , Edited by admin on Fri Dec 15 15:23:28 UTC 2023
PRIMARY
CHEBI
4858
Created by admin on Fri Dec 15 15:23:28 UTC 2023 , Edited by admin on Fri Dec 15 15:23:28 UTC 2023
PRIMARY
CAS
29975-16-4
Created by admin on Fri Dec 15 15:23:28 UTC 2023 , Edited by admin on Fri Dec 15 15:23:28 UTC 2023
PRIMARY
Related Record Type Details
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
Related Record Type Details
METABOLITE LESS ACTIVE -> PARENT
m. 1-0x0-estazolam was about five times less effective than the parent drug in terms of brain concn. necessary to disrupt rota-rod performance but only twice in respect to the anticonvulsant activity.
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE -> PARENT
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY